NTRANTRAHealthcare · Diagnostics & Research

NTRA Stock Forecast: Natera, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$273
−5.86% on the day

The 23 Wall Street analysts covering Natera, Inc. hold a median 12-month price target of $408 — +49.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 70 of 100 as at 21 Nov 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$39.6B
Ticker Nerd rank
70/ 100
Median analyst target
$408
Analysts covering
23
Revenue$752.8M+37.7% y/y
Operating income−$75.8M
Net income−$67.0M
Free cash flow−$8.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−14.5%
1M
−32.8%
YTD
+19.1%
1Y
+21.0%
From 52W high
−37.4%
From 52W low
+49.4%
$183
$436
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Natera, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
70/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
93
Quality
91
Growth
73
Revisions
64
Value
59
Volatility
57
Accruals
56
Issuance
27

Momentum (93): The shares have been drifting up relative to others.

Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NTRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NTRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$300$400$500Jan 26Apr 26Jul 26Oct 26NTRAHigh $500Median $408Low $280

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says23 analysts
21
Buy
2
Hold
0
Sell
$280
Low
$408
Median
$500
High

The green dot is the last close — the median target sits +49.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 16 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
9 Nov 2026BairdMaintainsOutperform$458 → $403
6 Nov 2026Evercore ISI GroupMaintainsOutperform$468 → $400
6 Nov 2026JP MorganMaintainsOverweight$460 → $405
27 Oct 2026BTIGMaintainsBuy$320 → $430
19 Oct 2026Canaccord GenuityMaintainsBuy$375 → $500
14 Oct 2026JP MorganMaintainsOverweight$360 → $460
13 Oct 2026Morgan StanleyMaintainsOverweight$355 → $435
13 Oct 2026TD CowenMaintainsBuy$340 → $480
7 Oct 2026BarclaysMaintainsOverweight$340 → $475
6 Oct 2026CitigroupMaintainsBuy$365 → $480
1 Oct 2026GuggenheimMaintainsBuy$360 → $475
25 Sept 2026RBC CapitalMaintainsOutperform$350 → $460
9 Sept 2026UBSMaintainsBuy$290 → $435
8 Sept 2026Rothschild & CoInitiatesBuy$385
13 Aug 2026CitigroupMaintainsBuy$315 → $365
12 Aug 2026GuggenheimMaintainsBuy$290 → $360
12 Aug 2026Piper SandlerMaintainsOverweight$249 → $364
12 Aug 2026Stephens & Co.MaintainsOverweight$305 → $350
7 Aug 2026BTIGMaintainsBuy$290 → $320
7 Aug 2026CitigroupMaintainsBuy$300 → $315

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NTRA.

Market Radar

This page is one stock. Monday covers all of them.

NTRA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NTRA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Natera, Inc. returned +21.0% against +6.9% for the S&P 500, dividends included.

NTRA vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26NTRAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NTRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
5
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
13.6×

Cheaper than 10% of US stocks

Price / book
21.1×

Cheaper than 3% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
34.1%

Higher than 80% of US stocks

Earnings growth (YoY)
—
Gross margin
64.5%

Higher than 78% of US stocks

Operating margin
−8.5%

Higher than 27% of US stocks

Net margin
−5.7%

Higher than 24% of US stocks

Returns & dividend
Return on equity
−10.6%

Higher than 36% of US stocks

Return on assets
−6.8%

Higher than 30% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Natera, Inc. has a market value of $39.6B and an enterprise value of $38.8B.

  • Revenue in the twelve months to 30 June 2026: $2.7B. The latest quarter grew 37.7% year on year.

  • Net income over the same four quarters: −$192.3M, a −7.1% net margin.

  • Free cash flow in the twelve months to 30 June 2026: $51.2M.

  • Shares outstanding: 143.6M.

  • Natera, Inc. employs 4,424 people — $612K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

NTRA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
NTRANatera, Inc.$39.6B70
IQVIQVIA Holdings, Inc.$40.5B83
WATWaters Corp.$43.2B52
MTDMettler-Toledo International, Inc.$34.1B96
AAgilent Technologies, Inc.$48.3B85
LHLabcorp Holdings, Inc.$30.4B88
ILMNIllumina, Inc.$29.1B95

Take a look at NTRA’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Natera, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about NTRA

What is the NTRA stock price forecast for 2026-2027?

The 23 Wall Street analysts covering Natera, Inc. have a median 12-month price target of $408, with estimates ranging from $280 to $500. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NTRA stock a buy right now?

Of the 23 analysts covering Natera, Inc., 21 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Natera, Inc. 70 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NTRA?

As at 21 Nov 2026, Natera, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).

Will NTRA stock go up?

No one can know that. What the data says: the median 12-month target from 23 analysts implies +49.3% from the last close, and Ticker Nerd's factor model ranks Natera, Inc. 70 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NTRA stock forecast for 2030?

No analyst covering Natera, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $280 to $500 over the next 12 months.

How has NTRA stock performed over the past year?

Natera, Inc. returned +21.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Natera, Inc. do?

Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use. The company focuses on oncology, women’s health, and organ health, using proprietary molecular assays and bioinformatics to help detect and monitor genetic conditions and disease-related changes from small blood samples.

Company

About Natera, Inc.

Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use. The company focuses on oncology, women’s health, and organ health, using proprietary molecular assays and bioinformatics to help detect and monitor genetic conditions and disease-related changes from small blood samples. Its current product portfolio includes prenatal screening, carrier screening, cancer monitoring, and transplant rejection assessment tests, serving physicians, hospitals, health systems, transplant centers, and biopharma partners. Natera’s tests are used to support areas such as reproductive health, cancer residual disease monitoring, recurrence surveillance, and organ transplant management. Headquartered in Austin, Texas, Natera plays an important role in the growing precision medicine market by providing non-invasive diagnostic tools that help inform clinical decision-making across multiple medical specialties.

CEO Mr. Steven Leonard Chapman · 4,424 employees · United States · https://www.natera.com